Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours

BACKGROUND: Bleomycin, etoposide, and cisplatin (BEP) chemotherapy administered every 3 weeks for 4 cycles remains the standard first line treatment for patients with intermediate- and poor-risk metastatic germ cell tumours (GCTs). Administering standard chemotherapy 2-weekly rather than 3-weekly, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Lawrence, Nicola J., Chan, Howard, Toner, Guy, Stockler, Martin R., Martin, Andrew, Yip, Sonia, Wong, Nicole, Yeung, Annie, Mazhar, Danish, Pashankar, Farzana, Frazier, Lindsay, McDermott, Ray, Walker, Roderick, Tan, Hsiang, Davis, Ian D., Grimison, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114870/
https://www.ncbi.nlm.nih.gov/pubmed/30157803
http://dx.doi.org/10.1186/s12885-018-4745-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114870/
https://www.ncbi.nlm.nih.gov/pubmed/30157803
http://dx.doi.org/10.1186/s12885-018-4745-3

Ejemplares similares